Relationship between serum intact parathyroid hormone concentrations and bone remodeling in type I osteoporosis: Evidence that skeletal sensitivity is increased

M. A. Kotowicz, G. G. Klee, P. C. Kao, W. M. O'Fallon, S. F. Hodgson, S. L. Cedel, E. F. Eriksen, Daryl G. Gonchoroff, H. L. Judd, B. L. Riggs

Research output: Contribution to journalArticle

44 Citations (Scopus)

Abstract

To define the role of parathyroid gland function in the pathophysiology of bone loss in type I (postmenopausal) osteoporosis, we measured serum intact parathyroid hormone (PTH) concentration by immunoradiometric assay (IRMA) and by multisite immunochemiluminometric assay (ICMA) in 63 postmenopausal osteoporotic women (PMOp) with vertebral compression fractures and in 75 age-comparable postmenopausal normal women (PMNl). Also, tetracycline-based histomorphometric indices in cancellous bone were assessed in iliac biopsy samples from 61 PMOp and 28 PMNl women. Serum PTH concentrations by IRMA were similar in PMOp and PMNl (medians, 3.92 and 3.77 pmol/l; NS) but were significantly lower in PMOp by the more sensitive ICMA (medians, 2.82 and 3.14 pmol/l;P<0.01). By multiple linear regression analysis, serum PTH was directly related (P<0.001) to activation frequency, bone resorption rate, bone formation rate, and the calculated rate of bone loss. For each unit (pmol/l) increase in serum PTH by ICMA, activation frequency increased by 1.3%/year more (P=0.01), bone resorption rate increased by 3.9%/year more (P=0.003), and the rate of cancellous bone loss was 2.8% greater (P= 0.0003) in the PMOp women compared with the PMNl women. Concentrations of serum estradiol, but not serum estrone, had a weak opposing effect to PTH, especially for bone formation rate. These data suggest that in PMOp the bone has increased sensitivity to the biologic effects of PTH. This may represent one of the fundamental pathophysiologic defects in PMOp and, in the setting of estrogen deficiency, may explain, in part, their greater rate of bone loss.

Original languageEnglish (US)
Pages (from-to)14-22
Number of pages9
JournalOsteoporosis International
Volume1
Issue number1
DOIs
StatePublished - Oct 1990

Fingerprint

Bone Remodeling
Parathyroid Hormone
Osteoporosis
Serum
Immunoradiometric Assay
Bone and Bones
Bone Resorption
Osteogenesis
Compression Fractures
Postmenopausal Osteoporosis
Parathyroid Glands
Estrone
Tetracycline
Estradiol
Linear Models
Estrogens

Keywords

  • Bone formation
  • Bone resorption
  • Osteoporosis
  • Parathyroid hormone (PTH)

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Relationship between serum intact parathyroid hormone concentrations and bone remodeling in type I osteoporosis : Evidence that skeletal sensitivity is increased. / Kotowicz, M. A.; Klee, G. G.; Kao, P. C.; O'Fallon, W. M.; Hodgson, S. F.; Cedel, S. L.; Eriksen, E. F.; Gonchoroff, Daryl G.; Judd, H. L.; Riggs, B. L.

In: Osteoporosis International, Vol. 1, No. 1, 10.1990, p. 14-22.

Research output: Contribution to journalArticle

Kotowicz, MA, Klee, GG, Kao, PC, O'Fallon, WM, Hodgson, SF, Cedel, SL, Eriksen, EF, Gonchoroff, DG, Judd, HL & Riggs, BL 1990, 'Relationship between serum intact parathyroid hormone concentrations and bone remodeling in type I osteoporosis: Evidence that skeletal sensitivity is increased', Osteoporosis International, vol. 1, no. 1, pp. 14-22. https://doi.org/10.1007/BF01880411
Kotowicz, M. A. ; Klee, G. G. ; Kao, P. C. ; O'Fallon, W. M. ; Hodgson, S. F. ; Cedel, S. L. ; Eriksen, E. F. ; Gonchoroff, Daryl G. ; Judd, H. L. ; Riggs, B. L. / Relationship between serum intact parathyroid hormone concentrations and bone remodeling in type I osteoporosis : Evidence that skeletal sensitivity is increased. In: Osteoporosis International. 1990 ; Vol. 1, No. 1. pp. 14-22.
@article{4660564e509548a6b8185ade7246954c,
title = "Relationship between serum intact parathyroid hormone concentrations and bone remodeling in type I osteoporosis: Evidence that skeletal sensitivity is increased",
abstract = "To define the role of parathyroid gland function in the pathophysiology of bone loss in type I (postmenopausal) osteoporosis, we measured serum intact parathyroid hormone (PTH) concentration by immunoradiometric assay (IRMA) and by multisite immunochemiluminometric assay (ICMA) in 63 postmenopausal osteoporotic women (PMOp) with vertebral compression fractures and in 75 age-comparable postmenopausal normal women (PMNl). Also, tetracycline-based histomorphometric indices in cancellous bone were assessed in iliac biopsy samples from 61 PMOp and 28 PMNl women. Serum PTH concentrations by IRMA were similar in PMOp and PMNl (medians, 3.92 and 3.77 pmol/l; NS) but were significantly lower in PMOp by the more sensitive ICMA (medians, 2.82 and 3.14 pmol/l;P<0.01). By multiple linear regression analysis, serum PTH was directly related (P<0.001) to activation frequency, bone resorption rate, bone formation rate, and the calculated rate of bone loss. For each unit (pmol/l) increase in serum PTH by ICMA, activation frequency increased by 1.3{\%}/year more (P=0.01), bone resorption rate increased by 3.9{\%}/year more (P=0.003), and the rate of cancellous bone loss was 2.8{\%} greater (P= 0.0003) in the PMOp women compared with the PMNl women. Concentrations of serum estradiol, but not serum estrone, had a weak opposing effect to PTH, especially for bone formation rate. These data suggest that in PMOp the bone has increased sensitivity to the biologic effects of PTH. This may represent one of the fundamental pathophysiologic defects in PMOp and, in the setting of estrogen deficiency, may explain, in part, their greater rate of bone loss.",
keywords = "Bone formation, Bone resorption, Osteoporosis, Parathyroid hormone (PTH)",
author = "Kotowicz, {M. A.} and Klee, {G. G.} and Kao, {P. C.} and O'Fallon, {W. M.} and Hodgson, {S. F.} and Cedel, {S. L.} and Eriksen, {E. F.} and Gonchoroff, {Daryl G.} and Judd, {H. L.} and Riggs, {B. L.}",
year = "1990",
month = "10",
doi = "10.1007/BF01880411",
language = "English (US)",
volume = "1",
pages = "14--22",
journal = "Osteoporosis International",
issn = "0937-941X",
publisher = "Springer London",
number = "1",

}

TY - JOUR

T1 - Relationship between serum intact parathyroid hormone concentrations and bone remodeling in type I osteoporosis

T2 - Evidence that skeletal sensitivity is increased

AU - Kotowicz, M. A.

AU - Klee, G. G.

AU - Kao, P. C.

AU - O'Fallon, W. M.

AU - Hodgson, S. F.

AU - Cedel, S. L.

AU - Eriksen, E. F.

AU - Gonchoroff, Daryl G.

AU - Judd, H. L.

AU - Riggs, B. L.

PY - 1990/10

Y1 - 1990/10

N2 - To define the role of parathyroid gland function in the pathophysiology of bone loss in type I (postmenopausal) osteoporosis, we measured serum intact parathyroid hormone (PTH) concentration by immunoradiometric assay (IRMA) and by multisite immunochemiluminometric assay (ICMA) in 63 postmenopausal osteoporotic women (PMOp) with vertebral compression fractures and in 75 age-comparable postmenopausal normal women (PMNl). Also, tetracycline-based histomorphometric indices in cancellous bone were assessed in iliac biopsy samples from 61 PMOp and 28 PMNl women. Serum PTH concentrations by IRMA were similar in PMOp and PMNl (medians, 3.92 and 3.77 pmol/l; NS) but were significantly lower in PMOp by the more sensitive ICMA (medians, 2.82 and 3.14 pmol/l;P<0.01). By multiple linear regression analysis, serum PTH was directly related (P<0.001) to activation frequency, bone resorption rate, bone formation rate, and the calculated rate of bone loss. For each unit (pmol/l) increase in serum PTH by ICMA, activation frequency increased by 1.3%/year more (P=0.01), bone resorption rate increased by 3.9%/year more (P=0.003), and the rate of cancellous bone loss was 2.8% greater (P= 0.0003) in the PMOp women compared with the PMNl women. Concentrations of serum estradiol, but not serum estrone, had a weak opposing effect to PTH, especially for bone formation rate. These data suggest that in PMOp the bone has increased sensitivity to the biologic effects of PTH. This may represent one of the fundamental pathophysiologic defects in PMOp and, in the setting of estrogen deficiency, may explain, in part, their greater rate of bone loss.

AB - To define the role of parathyroid gland function in the pathophysiology of bone loss in type I (postmenopausal) osteoporosis, we measured serum intact parathyroid hormone (PTH) concentration by immunoradiometric assay (IRMA) and by multisite immunochemiluminometric assay (ICMA) in 63 postmenopausal osteoporotic women (PMOp) with vertebral compression fractures and in 75 age-comparable postmenopausal normal women (PMNl). Also, tetracycline-based histomorphometric indices in cancellous bone were assessed in iliac biopsy samples from 61 PMOp and 28 PMNl women. Serum PTH concentrations by IRMA were similar in PMOp and PMNl (medians, 3.92 and 3.77 pmol/l; NS) but were significantly lower in PMOp by the more sensitive ICMA (medians, 2.82 and 3.14 pmol/l;P<0.01). By multiple linear regression analysis, serum PTH was directly related (P<0.001) to activation frequency, bone resorption rate, bone formation rate, and the calculated rate of bone loss. For each unit (pmol/l) increase in serum PTH by ICMA, activation frequency increased by 1.3%/year more (P=0.01), bone resorption rate increased by 3.9%/year more (P=0.003), and the rate of cancellous bone loss was 2.8% greater (P= 0.0003) in the PMOp women compared with the PMNl women. Concentrations of serum estradiol, but not serum estrone, had a weak opposing effect to PTH, especially for bone formation rate. These data suggest that in PMOp the bone has increased sensitivity to the biologic effects of PTH. This may represent one of the fundamental pathophysiologic defects in PMOp and, in the setting of estrogen deficiency, may explain, in part, their greater rate of bone loss.

KW - Bone formation

KW - Bone resorption

KW - Osteoporosis

KW - Parathyroid hormone (PTH)

UR - http://www.scopus.com/inward/record.url?scp=0025495379&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0025495379&partnerID=8YFLogxK

U2 - 10.1007/BF01880411

DO - 10.1007/BF01880411

M3 - Article

C2 - 2133635

AN - SCOPUS:0025495379

VL - 1

SP - 14

EP - 22

JO - Osteoporosis International

JF - Osteoporosis International

SN - 0937-941X

IS - 1

ER -